Alvotech is a specialty pharma. Over the past three years, Alvotech has been involved in 2 licensing and acquisition transactions, with a primary focus on Antibodies (3 deals). The company currently has 2 active clinical trials, primarily in Other.
Deals (12mo)
1
Active Trials
2
Top Modality
Antibodies
Focus Area
Other
Licensing, acquisition, and partnership transactions involving Alvotech in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Undisclosed | Lotus Pharmaceutical | Antibodies | Unknown | license | Aug 21, 2026 |
Therapeutic areas and modalities where Alvotech is most active based on deal history and clinical trial data.
Alvotech has 2 active clinical trials across 2 development phases.
1
Phase 1
1
Phase 3
Use Solidus to benchmark upfront payments, milestones, and royalties for Other assets — powered by data from 3,500+ real biopharma transactions.
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
Alvotech is a specialty pharma company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Alvotech ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alvotech include Other (2 deals and trials), Ophthalmology (1 deal and trial), Solid Tumors (1 deal and trial), and Metabolic (1 deal and trial). In terms of modality, Alvotech has shown particular interest in antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alvotech and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Alvotech's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.